Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claims provided are not medical claims about indications, dosing, safety, warnings, or interactions; they concern identity/marketing. FDA label excerpts supplied do not address manufacturer/marketing attribution, so these items cannot be validated against the provided label but are not contradicted by it.
Category Scores
Accurate Statements
Livalo is the brand name for pitavastatin.
Supported for drug identity: label excerpts refer to LIVALO (pitavastatin) tablets and state mechanism of action for pitavastatin.
Unsupported Statements
Livalo is made by Recordati (through its affiliate Recordati Ireland Ltd.).
Not supported by the supplied FDA label excerpts (no manufacturer/affiliate attribution provided).
Livalo is marketed in the U.S. by Upsher-Smith Laboratories, LLC.
Not supported by the supplied FDA label excerpts (no U.S. marketing/label distributor information provided).
Contradictions
Important Omissions
None—no indication, dosing, contraindication, warnings/precautions, drug interaction, or population-specific safety claims were made that would require labeling verification.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Claims are limited to product identity and company attribution; no dosing/safety clinical claims were made that could mislead regarding risk.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Two company attribution claims are not supported by the provided label excerpts.
Suggested Improvement
Limit statements to label-supported identity information (e.g., LIVALO = pitavastatin) or provide label excerpts that explicitly include manufacturer/marketing attribution.